Milo Mitchell/UCLA Jonsson Comprehensive Cancer Center
Slamon was honored for ’groundbreaking contributions to the clinical development of targeted therapy directed against genetic aberrations in cancer.’
Scientist whose work led to development Herceptin honored for innovations in molecularly targeted treatments. Denise Heady Dr. Dennis Slamon, director of the Revlon/UCLA Women's Cancer Research Program, has been named a co-winner of the 2019 Sjöberg Prize by the Royal Swedish Academy of Sciences and Sweden's Sjöberg Foundation. Honored for his groundbreaking research that led to the development of successful targeted cancer therapies, Slamon shares the award with Dr. Brian Druker of Oregon Health & Science University. The Sjöberg Prize has been awarded annually since 2016 to recognize outstanding cancer research. The honor carries a prize of $1 million — $100,000 as award money and $900,000 to fund future research — which Slamon and Druker will split equally. Among the previous honorees is Dr. James Allison of the University of Texas MD Anderson Cancer Center, who went on to win the Nobel Prize in physiology or medicine for 2018. Slamon, who also is director of clinical and translational research at the UCLA Jonsson Comprehensive Cancer Center , was selected for his " groundbreaking contributions to the clinical development of targeted therapy directed against genetic aberrations in cancer, " according to the Royal Swedish Academy.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
